NCT06671431Completed
Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma
Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma: a Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 4 Nov 2024
Brief summary (registry, in English)
Recent studies addressing the role of adjuvant chemotherapy in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability. Therefore, the aim of this study was to investigate the role of AC in distal cholangiocarcinoma, a common tumor subtype of CCA.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 578 (actual)
- First submitted
- 31 Oct 2024
- Start date
- 1 Jan 2000
- Primary completion date
- 31 Dec 2021
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06671431
What you commit to
- Study type: Observational
- Participants enrolled: 578
- From 1 Jan 2000 to the primary completion date, 31 Dec 2021
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Who underwent R2 resection
- Death within 90days of surgery
Other
- Who underwent neoadjuvant treatment
- Non-adenocarcinoma patients in final pathology report
- Insufficient data
Who the study is looking for
- Patients with distal cholangiocarcinoma who underwent surgery
Age in the registry: 19 years to 90 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.